Press Releases
-
BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results
-
SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, collaborating with IQVIA Brazil published an article on December 17 titled “
-
Beijing, China, December 24, 2021 – SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced resu
-
Current SINOVAC Directors Elected Properly at the 2018 Annual General Meeting The Company's Rights Agreement is Valid under Antigua LawDecember 9, 2021 -- BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SV
-
Instituto Butantan, in partnership with Sinovac Biotech, is pleased to announce CoronaVac® Symposium, an international online event that aims to promote and discuss the latest results of the efficacy
-
CoronaVac® generates good immune memory after second doseThird dose of vaccine significantly increased neutralizing antibody levels in adults and elderly populationFindings indicate a third dose of Co
-
CoronaVac® generates good immune memory after the second doseThird dose of CoronaVac® induces strong immune response No serious adverse reactions reportedAdverse reactions reported within 28 day after
-
BEIJING, China, July 19, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced CoronaV
-
SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it received a drug registration approval